Latest Breaking News On - Jessicaj lin - Page 1 : vimarsana.com

Improved Outcomes With Subcutaneous Amivantamab in NSCLC

Subcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.

'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

Nuvalent: Strong Data, But Properly Valued (NASDAQ:NUVL)

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response1 Augtyro adds to Bristol Myers Squibb’s growing.

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Bristol-Myers Squibb (BMY) Announces FDA Approval of Augtyro

FDA OKs New Option for Advanced ROS1-Positive Lung Cancer

Drug achieved high response rates in TKI-naive and TKI-pretreated patients

FDA Approves Augtyro for Patients With NSCLC Subset

The Food and Drug Administration approved Augtyro for patients with ROS1-positive metastatic non-small cell lung cancer based on a phase 1/2 trial.

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.

FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC

Repotrectinib is a tyrosine kinase inhibitor (TKI) that targets ROS1 and is administered as an oral therapy for treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer.